ARF6 Antibody Selection: Mechanisms, Detection Pitfalls, and Validation Data

ARF6 as a Membrane Trafficking Switch

ARF6 (ADP-ribosylation factor 6) belongs to the ARF family of small GTPases. It works as a molecular switch for membrane dynamics, cycling between a GTP-bound active state and a GDP-bound inactive state. Through that cycle it controls plasma membrane dynamics, endosomal trafficking, and actin cytoskeleton remodeling. The product page lists its cellular localization as cytoplasm, endosome, and cell membrane, with the sequence traceable to UniProt accession P62330.

Unlike other ARF isoforms that mainly serve Golgi trafficking, ARF6 uniquely resides at the plasma membrane and endosomes. There it coordinates clathrin-independent endocytosis and the recycling of membrane proteins such as integrins and MHC class I molecules. It also drives membrane ruffling and lamellipodia formation through downstream effectors including JIP3/4, POR1, and phospholipase D.

GEFs and GAPs Time the Cycle

ARF6 activity is controlled in both space and time. Guanine nucleotide exchange factors such as EFA6 and cytohesin switch the protein on. GTPase-activating proteins such as ACAP and GIT switch it off. That pairing keeps cell migration, adhesion, phagocytosis, and pathogen entry orderly. When the timing breaks down, the same processes become disorganized, which is why the target appears in so many disease contexts.

Disease Associations: Metastasis, Neurons, and Pathogen Entry

The product page frames ARF6 disease relevance around dysregulated membrane trafficking and cytoskeletal rearrangement, spanning cancer metastasis, neurological disorders, and infectious disease. In cancer, the logic centers on migration and adhesion, since ARF6 drives integrin recycling and membrane ruffling that determine how tumor cells move. In neurology, the focus is how abnormal membrane protein recycling affects neuronal function. In infection, the link runs through ARF6-dependent pathogen entry pathways.

As a detection target, ARF6 has an awkward profile: small, widely expressed, and diffusely localized. Broad expression means positive controls are easy to source. Diffuse localization means immunohistochemistry demands solid histology, because staining intensity alone is not enough and the distribution pattern must also make sense for the tissue being examined.

Why a 20 kDa Target Punishes Careless Conditions

The product page lists both predicted and observed molecular weight as 20 kDa. Low-molecular-weight proteins need an adequately concentrated separation gel and a moderate run time. During transfer they can pass straight through the membrane. When conditions are off, the band turns weak or vanishes, and the loss is routinely misread as insufficient antibody sensitivity.

Localization adds a second variable. Because ARF6 partitions between cytoplasm, endosome, and cell membrane, the balance between membrane-bound and soluble pools shifts with cell state. Lysis buffer detergent strength therefore changes how much ARF6 a lysate actually yields. Running a positive control lysate alongside the experimental samples is the simplest way to separate a genuine negative result from a failed transfer.

Western blot of ARF6 across six human cell line lysates, with a single band at approximately 20 kDa labeled ARF6 and lanes 1 to 6 corresponding to 293T, MCF7, A-431, HeLa, Hep G2, and A549

Western blot of ARF6 in tissue and rat cell lysates, showing a band at approximately 20 kDa labeled ARF6 across PC-12 cells, rat kidney, and rat liver

Reading the Immunohistochemistry Panel

The immunohistochemistry protocol on the product page uses Tris/EDTA buffer at pH 9.0 for heat-induced antigen retrieval with the primary antibody at 1:2000. Validation covers human kidney, human stomach, human breast cancer, human gastric cancer, and human thyroid cancer. Because ARF6 staining is diffuse rather than sharply compartmentalized, interpretation improves when the tissue type is recorded alongside the pattern and the intensity. Negative controls are not documented on the product page for these images. A matched isotype control run in parallel therefore remains good practice before the reagent enters a formal scoring workflow.

Immunohistochemistry of paraffin-embedded human kidney stained for ARF6, showing brown cytoplasmic signal in tubular epithelium with hematoxylin counterstain

Immunohistochemistry of paraffin-embedded human breast cancer tissue stained for ARF6, showing brown cytoplasmic signal in tumor cells with hematoxylin counterstain

What the Validation Panel Tells You

The cell-line panel is deliberately varied. Adherent lines such as HeLa and A549, a macrophage line (RAW 264.7), and fibroblasts (NIH/3T3) represent one set of trafficking states. A neuronal line (PC-12) and a monkey fibroblast line (COS7) add further diversity. When a single band at 20 kDa appears across that spread, the antibody is more likely reporting the target than an extraction artifact. The tissue blots apply the same logic to kidney and liver, where endosomal traffic is heavy and background is usually elevated.

The Tissue Expression Atlas

Beyond individual sections, the product page summarizes ARF6 distribution across a panel of human tumor tissues. Broad positivity across breast, cervical, renal, liver, ovarian, thyroid, prostate, lung, colon, gastric, endometrial, and pancreatic cancer is reported. That breadth supports the view that ARF6 expression is not restricted to one tumor type. For a low-molecular-weight target, that breadth is practical: it supplies multiple independent chances to confirm a positive signal.

Table of ARF6 expression across human tumor tissues, listing positive staining for breast, cervical, kidney, liver, ovarian, thyroid, prostate, lung, colon, gastric, endometrial, pancreatic cancer, and tonsil

Product Specification and Validation Summary

Reactive species are listed as human, mouse, rat, and monkey, and Western blot recommendations match that range. For IHC-P the recommended species narrows to human only, and predicted reactive species are not listed, so histological validation in other species has to be confirmed independently. On the cell level, validation data cover 293T, MCF7, A-431, HeLa, Hep G2, A549, RAW 264.7, NIH/3T3, PC-12, and COS7. On the tissue level, they cover mouse and rat kidney and liver along with the human tissues listed above. Each lot ships with a datasheet and a certificate of analysis, and the sequence remains traceable to UniProt accession P62330.

Conclusion

ARF6 is difficult because it is both small and dispersed. A 20 kDa band requires the right gel percentage and transfer time, and the diffuse localization requires reading tissue context together with the staining pattern. ANT BIO PTE. LTD. validates this reagent across human, mouse, rat, and monkey sources at the cell level, which gives laboratories several independent ways to confirm a signal. For a target this size, the practical order of work is clear: fix the electrophoresis and transfer conditions first, then judge specificity. Recording gel percentage, transfer duration, and membrane type alongside each result turns that troubleshooting into a reproducible method rather than a matter of memory.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

ANT BIO PTE. LTD. supplies high-quality reagents and solutions for life science research. Our sub-brands cover the full research workflow: Starter for antibodies and immunological assay kits, UA-Bio for recombinant proteins and drug discovery solutions, and Absin for general reagents and other detection kits. Explore our product portfolio at www.antbioinc.com.

Disclaimer

This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.